How and Why Can MEEXXVI Surpass GLP-1s?
The Hidden Secrets VS the MEEOM® Precision Medicine Weigh Management Project (MPMWMP)
No side effects [1] [2] [3] [4].
98.5% Success Rate*
99% Satisfaction Rate**
People using GLP-1 injections to lose weight should be aware of real chance of developing severe inflammation of the pancreas, known as acute pancreatitis [1].
In the Phase 1 study, TERN-601 produced dose-dependent weight loss over 28 days, with statistically significant reductions versus placebo at all doses. Treatment was associated with GLP-1–consistent pharmacodynamic effects, including reduced appetite and delayed gastric emptying. In the Phase 2 study, TERN-601 doses ≥ 500 mg resulted in significantly greater mean percentage weight loss at Week 12 versus placebo. Gastrointestinal treatment-emergent adverse events were consistent with the GLP-1 receptor agonist class and dose-related. Three participants in the Phase 2 study experienced transaminase elevations consistent with potential drug-induced liver injury.
TERN-601 demonstrated modest, dose-dependent weight loss with a gastrointestinal tolerability profile consistent with GLP-1 receptor agonists. However, liver safety findings observed in the Phase 2 study led to clinical development discontinuation. These data contribute to the overall understanding of oral small-molecule GLP-1 receptor agonists in obesity. [2]
A comparison of data from 12,004 GLP-1RA users and 15,221 SGLT-2 inhibitor users revealed a 37% higher risk of hair loss in the former group; a comparison involving 11,964 GLP-1RA users and 11,233 DPP-4 inhibitor users showed a 68% higher risk of hair loss among GLP-1RA users. The GLP-1RAs analyzed included six agents: semaglutide, tirzepatide, liraglutide, dulaglutide, exenatide, and lixisenatide [3].
Fig. 5. Genetic associations with GLP1 medication side effects [4]. From: Genetic predictors of GLP1 receptor agonist weight loss and side effects
a, Manhattan plot of experiencing moderate-to-severe vomiting while on tirzepatide treatment. SNPs achieving genome-wide significance (P < 5 × 10−8) are highlighted in red. b, Regional plot around the GIPR locus. Colours indicate strength of linkage disequilibrium (r2) relative to the index SNP (rs71338792). Note that the probable causal missense variant, rs1800437, is located within the cluster of significant SNPs and is in very high linkage disequilibrium with the index SNP (r2 = 0.99). Non-coding variants are indicated with plus symbols; coding variants are indicated with multiplication symbols. c, Estimated effect sizes of rs1800437 in the vomiting side effect, partitioned by drug type, for Europeans, Latinos and a fixed effect meta-analysis. Circles, point estimates; horizontal bars, 95% confidence intervals (CI). OR, odds ratio. (Nature (Nature) ISSN 1476-4687 (online) ISSN 0028-0836 (print))
The development of glucagon-like peptide 1 (GLP1) receptor agonists, including semaglutide and tirzepatide, has transformed the clinical management of overweight and obesity. However, substantial inter-person variability exists in both weight loss efficacy and the incidence of side effects1. To investigate the genetic basis of this variability, here we conduct a genome-wide association study of self-reported weight loss and treatment-related side effects in 27,885 people following GLP1 receptor agonist therapy. We identify a missense variant in GLP1R that is associated significantly with increased efficacy of GLP1 medications (P = 2.9 × 10−10), with an additional −0.76 kg of weight loss expected per copy of the effect allele. Furthermore, we identify associations linking variation in both GLP1R and GIPR to GLP1 medication-related nausea or vomiting, with the GIPR association being restricted to people using tirzepatide. We incorporate these findings into a broader model of GLP1 medication response, and demonstrate the ability to stratify patients by efficacy and side effect risk. These findings provide direct genetic evidence that variation in the drug target genes contributes to inter-person variability in response and lay the foundation for precision medicine approaches in the treatment of obesity [4].
You have a better choice.
You do not need to try to "outsmart" human evolutionary mechanisms by tricking hypothalamic circuits—which is precisely how GLP-1RA drugs work to regulate pre-meal satiety [5].
Genetic variants in GLP1R and GIPR, which encode targets of GLP-1-based medications, offer insights into why responses to these drugs vary and who might face adverse effects. [6].
The MEEOM® Precision Medicine Weigh Management Project (MPMWMP) is safe, effective, and suitable for everyone, anytime, anywhere. No need to starve—lose only fat (including visceral fat) without losing muscle! You can take control of when you lose weight and decide exactly how much weight to shed, all while maintaining a calm state of mind.
Take action NOW.
Healthier, Wealthier & Happier, MEEOM®.
Yours truly,
Lisa Lee
Secretary-General
MEEOM® WorldWide Health Systems
MEEOM® Precision Medicine
MEEOM® プレシジョンメディシン
3-1-1 Kyobashi
Chuo-ku
Tokyo
104-0031
Facts Talk.事実を話させてください。
MEEOM® Members (GM, BDEM) ONLY.
Fig. 1. Photo Credit Getty Images
*Based on 31,600 MEEXXVI Clinical Trials by Meeomers Worldwide
**5000 random phone interviews by MMRC, May 29, 2026
Reference:s
[1]https://www.bbc.com/news/articles/cr57jzz9jvno
[2] Garvey W.T., Julio Rosenstock J, Bays H.E., Denham D, et al. Oral GLP-1RA TERN-601 for Adults With Obesity/Overweight: Placebo-Controlled, Multiple-Ascending-Dose, Phase 1 and 2 Studies. First published: 30 July 2026, https://doi.org/10.1002/oby.70271
[3] Tang, H., Zhang, B., Lu, Y., Zhang, D., Liu, R., Lu, Y., Cotsarelis, G., Asch, D. A., & Chen, Y. (2026). Risk of hair loss associated with glucagon-like peptide-1 receptor agonists in adults with type 2 diabetes: target trial emulation. BMJ, 394, e100077. https://doi.org/10.1136/bmj-2026-100077
[4] Su, Q.J., Ashenhurst, J.R., Xu, W. et al. Genetic predictors of GLP1 receptor agonist weight loss and side effects. Nature 653, 770–775 (2026). https://doi.org/10.1038/s41586-026-10330-z
[5]. Kim KS, Park JS, Hwang E, et al. GLP-1 increases preingestive satiation via hypothalamic circuits in mice and humans. Science. Published online June 27, 2024. doi:10.1126/science.adj2537
[6]. Ruth J. F. Loos Genetics reveal why people respond differently to GLP-1 weight-loss drugs Nature 653 (2026). https://www.nature.com/articles/d41586-026-00905-1
